Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
Programmed death 1 (PD-1), an immunoinhibitory receptor, and programmed death ligand 1 (PD-L1), its ligand, together induce the "exhausted" status in antigen-specific lymphocytes and are thus involved in the immune evasion of tumor cells. In this study, canine PD-1 and PD-L1 were molecular...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/274bebba5da1467db46e1e7a242b93a0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:274bebba5da1467db46e1e7a242b93a0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:274bebba5da1467db46e1e7a242b93a02021-11-18T08:16:15ZExpression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.1932-620310.1371/journal.pone.0098415https://doaj.org/article/274bebba5da1467db46e1e7a242b93a02014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24915569/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Programmed death 1 (PD-1), an immunoinhibitory receptor, and programmed death ligand 1 (PD-L1), its ligand, together induce the "exhausted" status in antigen-specific lymphocytes and are thus involved in the immune evasion of tumor cells. In this study, canine PD-1 and PD-L1 were molecularly characterized, and their potential as therapeutic targets for canine tumors was discussed. The canine PD-1 and PD-L1 genes were conserved among canine breeds. Based on the sequence information obtained, the recombinant canine PD-1 and PD-L1 proteins were constructed; they were confirmed to bind each other. Antibovine PD-L1 monoclonal antibody effectively blocked the binding of recombinant PD-1 with PD-L1-expressing cells in a dose-dependent manner. Canine melanoma, mastocytoma, renal cell carcinoma, and other types of tumors examined expressed PD-L1, whereas some did not. Interestingly, anti-PD-L1 antibody treatment enhanced IFN-γ production from tumor-infiltrating cells. These results showed that the canine PD-1/PD-L1 pathway is also associated with T-cell exhaustion in canine tumors and that its blockade with antibody could be a new therapeutic strategy for canine tumors. Further investigations are needed to confirm the ability of anti-PD-L1 antibody to reactivate canine antitumor immunity in vivo, and its therapeutic potential has to be further discussed.Naoya MaekawaSatoru KonnaiRyoyo IkebuchiTomohiro OkagawaMami AdachiSatoshi TakagiYumiko KagawaChie NakajimaYasuhiko SuzukiShiro MurataKazuhiko OhashiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e98415 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Naoya Maekawa Satoru Konnai Ryoyo Ikebuchi Tomohiro Okagawa Mami Adachi Satoshi Takagi Yumiko Kagawa Chie Nakajima Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| description |
Programmed death 1 (PD-1), an immunoinhibitory receptor, and programmed death ligand 1 (PD-L1), its ligand, together induce the "exhausted" status in antigen-specific lymphocytes and are thus involved in the immune evasion of tumor cells. In this study, canine PD-1 and PD-L1 were molecularly characterized, and their potential as therapeutic targets for canine tumors was discussed. The canine PD-1 and PD-L1 genes were conserved among canine breeds. Based on the sequence information obtained, the recombinant canine PD-1 and PD-L1 proteins were constructed; they were confirmed to bind each other. Antibovine PD-L1 monoclonal antibody effectively blocked the binding of recombinant PD-1 with PD-L1-expressing cells in a dose-dependent manner. Canine melanoma, mastocytoma, renal cell carcinoma, and other types of tumors examined expressed PD-L1, whereas some did not. Interestingly, anti-PD-L1 antibody treatment enhanced IFN-γ production from tumor-infiltrating cells. These results showed that the canine PD-1/PD-L1 pathway is also associated with T-cell exhaustion in canine tumors and that its blockade with antibody could be a new therapeutic strategy for canine tumors. Further investigations are needed to confirm the ability of anti-PD-L1 antibody to reactivate canine antitumor immunity in vivo, and its therapeutic potential has to be further discussed. |
| format |
article |
| author |
Naoya Maekawa Satoru Konnai Ryoyo Ikebuchi Tomohiro Okagawa Mami Adachi Satoshi Takagi Yumiko Kagawa Chie Nakajima Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi |
| author_facet |
Naoya Maekawa Satoru Konnai Ryoyo Ikebuchi Tomohiro Okagawa Mami Adachi Satoshi Takagi Yumiko Kagawa Chie Nakajima Yasuhiko Suzuki Shiro Murata Kazuhiko Ohashi |
| author_sort |
Naoya Maekawa |
| title |
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| title_short |
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| title_full |
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| title_fullStr |
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| title_full_unstemmed |
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. |
| title_sort |
expression of pd-l1 on canine tumor cells and enhancement of ifn-γ production from tumor-infiltrating cells by pd-l1 blockade. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/274bebba5da1467db46e1e7a242b93a0 |
| work_keys_str_mv |
AT naoyamaekawa expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT satorukonnai expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT ryoyoikebuchi expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT tomohirookagawa expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT mamiadachi expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT satoshitakagi expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT yumikokagawa expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT chienakajima expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT yasuhikosuzuki expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT shiromurata expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade AT kazuhikoohashi expressionofpdl1oncaninetumorcellsandenhancementofifngproductionfromtumorinfiltratingcellsbypdl1blockade |
| _version_ |
1718421973577498624 |